Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rapport Therapeutics, Inc. (RAPP)
Company Research
Source: GlobeNewswire
BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST. A live and archived webcast of the presentation will be available in the “Investors” section of the company’s website at: https://investors.rapportrx.com. About Rapport Therapeutics Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their fin
Show less
Read more
Impact Snapshot
Event Time:
RAPP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RAPP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RAPP alerts
High impacting Rapport Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RAPP
News
- Rapport Therapeutics (NASDAQ:RAPP) was given a new $51.00 price target on by analysts at Wells Fargo & Company.MarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RAPP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $47.00 price target on the stock.MarketBeat
RAPP
Earnings
- 11/6/25 - Beat
RAPP
Sec Filings
- 12/18/25 - Form 4
- 12/17/25 - Form 144
- 12/17/25 - Form 144
- RAPP's page on the SEC website